Pathos AI Acquires Majority Stake in DeuterOncology to Advance Next-Generation MET Inhibitor Identified by Pathos Foundry Platform

New York, NY — May 6, 2026 — Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced the acquisition of a majority stake in DeuterOncology, a Belgium-based company developing DO-2, a third-generation MET kinase inhibitor for patients with MET-altered cancers. The asset was systematically identified, evaluated, and advanced to acquisition through the Pathos Foundry platform.

Identified by Foundry

As part of its core operations, Pathos utilizes Foundry to continuously analyze large-scale clinical and scientific datasets, including conference proceedings, regulatory filings, published trial data, and proprietary real-world evidence. This enables Pathos to identify high-potential, undervalued oncology assets in a systematic and unbiased way.

In late 2025, Foundry flagged DO-2 as a top-ranked candidate based on its mechanism of action, pharmacokinetic profile, early clinical signal, and probability of success relative to the competitive landscape. Foundry then evaluated its clinical merit, translational feasibility, competitive positioning, and acquisition viability to generate a composite recommendation. The entire process, from initial identification to management’s final investment decision, was completed in a fraction of the time required by traditional due diligence.

“The traditional approach to finding clinical assets is built on relationships, conference presence, and reputation. Foundry is built on data,” said Iker Huerga, CEO of Pathos AI. “It evaluates every asset purely on its merits — mechanism, pharmacokinetics, clinical signal, and probability of success. DO-2 scored at the top of our models. Ultimately, the best molecule wins.”

A Highly Differentiated MET Inhibitor

MET inhibitors are an established therapeutic class for MET-altered Non-Small Cell Lung Cancer (NSCLC), but every approved agent is limited by peripheral edema rates of 62-82%, frequently requiring dose reductions and treatment discontinuation.

DO-2’s deuterated structure and “fast on / fast off” binding kinetics deliver potent MET inhibition for 8-12 hours per day. This provides sufficient target coverage for robust antitumor activity without causing the sustained endothelial damage that drives chronic edema.

In a Phase 1 study of 28 patients, DO-2 demonstrated 100% tumor shrinkage in all evaluable MET exon 14 skipping NSCLC patients (10/10). It also demonstrated a superior safety profile with zero Grade 4 adverse events, and a peripheral edema rate of just 5% (versus 62-82% for competitors), and a highly convenient 60 mg once-daily oral dose. Patent exclusivity extends to December 2040.

“Pathos’s ability to recognize the potential of this program through rigorous, data-driven analysis is exactly the kind of conviction that will bring DO-2 to the patients who need it,” said Dr. Timothy Perera, Founder and CEO of DeuterOncology.

Powered by Foundry

Foundry doesn't just find drugs. It develops them. The platform is composed of thousands of AI agents working in parallel, powered by the Pathos Oncology Foundation Model. These agents identify undervalued assets and propose portfolio decisions for management. Throughout the entire development lifecycle, Foundry continuously analyzes the totality of emerging data to ensure Pathos programs maintain the highest possible probability of success while directly supporting clinical trial execution.

The same system that identified DO-2 will now guide its clinical development. DO-2 is one of four major portfolio decisions made through Foundry in Q1 2026 alone.

“We are not interested in process automation. We are redesigning drug development from first principles,” said Huerga. “DO-2 is proof that the system works.”

About Pathos AI

Pathos AI is an AI and technology company advancing its own pipeline of cancer therapies. Its Foundry platform redesigns drug development from first principles: identifying undervalued clinical assets, making portfolio decisions with continuously updated probability-of-success calculations, and executing clinical trials with AI-native monitoring. Pathos pipeline includes clinical-stage programs in mCRPC and MET-altered NSCLC, with active partnerships with AstraZeneca and Tempus AI.

About DeuterOncology

DeuterOncology is a Belgium-based company developing DO-2, a deuterated third-generation MET kinase inhibitor designed to deliver potent antitumor activity without the tolerability limitations of current MET-targeted therapies. DO-2 has completed Phase 1 dose escalation across eight clinical sites in the Netherlands, Belgium, and France.

Forward-Looking Statements

This press release contains forward-looking statements. These statements involve risks and uncertainties that may cause actual results to differ materially. Pathos AI undertakes no obligation to update any forward-looking statement.

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

October 23, 2026

Tempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to license the dataset under a five-year, $55 million agreement Pathos’s AI expertise and agentic AI platform, Foundry, combined with Bristol Myers Squibb’s (BMS) neuroscience drug development expertise to be applied to understanding disease progression and advancing new therapies BMS leads Pathos’s Series E financing and gains non-exclusive strategic access to Pathos’s AI platform, Pathos Foundry, across its broader portfolio, along with three-year exclusive rights to support its neuroscience development programs NEW YORK, October 23, 2026 — Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb (NYSE: BMY, “BMS”) and Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) to build a specialized, curated dataset and agentic AI capabilities for Alzheimer’s disease and other neurological conditions. BMS also leads Pathos’s Series E financing and gains access to Pathos Foundry across its broader R&D portfolio. Tempus will apply the infrastructure and expertise it has built in oncology to create a comprehensive, de-identified, longitudinal dataset from hundreds of thousands of patients with neurological conditions, designed to track outcomes over time and accelerate biological insight. Pathos will license the data from Tempus under a five-year, $55 million agreement. Pathos will apply its AI platform, Pathos Foundry, to interrogate the dataset at scale, generate and test hypotheses on disease biology, and inform the design of more targeted, adaptive clinical trials. Pathos built and validated this approach in oncology, where it guides decisions across the company’s clinical-stage pipeline, including adapting trial design in real time to improve its projected probability of success. The collaboration builds on BMS's broader strategy to combine advanced AI with deep scientific and disease-area expertise to make faster, higher-confidence decisions that drive innovation for patients. BMS is helping expand the application of Pathos Foundry into neuroscience, securing three-year exclusive rights in an area where the company brings deep research, clinical-development expertise and a growing portfolio of programs in Alzheimer’s disease and other neurological conditions. Through multi-year access to the platform across its broader portfolio and the specialized dataset developed through the definitive agreements, BMS aims to generate deeper insights into disease progression, identify patients most likely to benefit from potential therapies and design more precise clinical trials. “Neurological diseases demand more than any one company can bring on its own: the best longitudinal data, AI that can reason over it at scale, and the drug development expertise to turn insight into medicines,” said Iker Huerga, CEO of Pathos AI. “Intelligence alone does not bring a therapy to market. These collaborations bring all three together. We are thrilled to deepen our work with Tempus and proud to have BMS leading our Series E as we build a self-learning drug development system designed to adapt clinical trials and improve the likelihood of success.” “AI has the greatest potential when it is grounded in high-quality data and applied by scientists with deep understanding of diseases and drug development,” said Simon Davies, SVP, Head of Data and Quantitative Sciences, Bristol Myers Squibb. “Our investment in Pathos reflects our commitment to applying advanced AI and data science across research and development to accelerate innovation for patients. By combining AI-driven insights with our neuroscience expertise, we hope to deepen our understanding of disease progression, improve clinical-trial design and ultimately advance new treatment options. Collaborating with Pathos and Tempus allows us to interrogate Alzheimer’s and other neurological diseases at scale, strengthening our pipeline and advancing precision medicine for patients in need.” “Making meaningful progress against a disease as devastating as Alzheimer’s requires unprecedented data scale and computing power,” said Eric Lefkofsky, Founder and CEO of Tempus. “These collaborations unite BMS’s deep expertise, Pathos’s drug development agentic AI and Tempus’ data infrastructure. Together, we have a unique opportunity to uncover novel insights and accelerate much-needed treatments for Alzheimer’s patients.” About Pathos AI Pathos AI is an AI and technology company developing drugs. The company redesigns drug development from first principles: identifying clinical assets, making portfolio decisions with continuously updated probability-of-success calculations, and guiding clinical trials with AI-native monitoring. Pathos’s pipeline includes clinical-stage programs in metastatic castration-resistant prostate cancer, multiple myeloma, MET-altered non-small-cell lung cancer, ER+/HER2‐ breast cancer, and TROP2/HER3-expressing solid tumors. The company is based in New York City. For more information, visit pathos.com .